ReviewInternational journal of environmental research and public health2016
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.
Review in International journal of environmental research and public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Prognostic Value of Mismatch Repair Genes for Patients With Colorectal Cancer: Meta-Analysis.Technology in cancer research & treatment · 2018Pooled it
- ZIC2 drives colorectal cancer progression by regulating QPRT-mediated cell migration.Frontiers in immunology · 2026Article
- E2F transcription factors as multimodal biomarkers for pan-cancer management.Scientific reports · 2025Article
- The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review.Journal of gastrointestinal oncology · 2024Review
- Case report: Pathological and genetic features of pancreatic undifferentiated carcinoma with osteoclast-like giant cells.Pathology oncology research : POR · 2023Article
- Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives.International journal of molecular sciences · 2022Review
- Systematic analysis of the role of SLC52A2 in multiple human cancers.Cancer cell international · 2022Article
- Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma.Frontiers in genetics · 2022Article
- Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.The Journal of surgical research · 2021Article
- Article
- LDH-A negatively regulates dMMR in colorectal cancer.Cancer science · 2021Article
- Stage migration resulting from inadequate number of examined lymph nodes impacts prognosis in stage II colon cancer after radical surgery.International journal of colorectal disease · 2021Article
- The Mechanistic Roles of ncRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer.Non-coding RNA · 2021Review
- The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses.Frontiers in oncology · 2021Review
- Drug Resistance of CPT-11 in Human DLD-1 Colorectal Cancer Cells through MutS Homolog 2 Upregulation.International journal of medical sciences · 2021Article
- Zic Family Member 2 (ZIC2): a Potential Diagnostic and Prognostic Biomarker for Pan-Cancer.Frontiers in molecular biosciences · 2021Article
- RFWD3 Participates in the Occurrence and Development of Colorectal CancerFrontiers in cell and developmental biology · 2021Article
- High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer.Frontiers in oncology · 2021Article
- Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.Cell death & disease · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) represents the third most common type of cancer in developed countries and one of the leading causes of cancer deaths worldwide. Personalized management of CRC has gained increasing attention since there are large inter-individual variations in the prognosis and response to drugs used to treat CRC owing to molecular heterogeneity. Approximately 15% of CRCs are caused by deficient mismatch repair (dMMR) characterized by microsatellite instability (MSI) phenotype. The present review is aimed at highlighting the role of MMR status in informing prognosis and personalized treatment of CRC including adjuvant chemotherapy, targeted therapy, and immune checkpoint inhibitor therapy to guide the individualized therapy of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.